Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 72.5822
- Book/Share 29.5489
- PB 35.824
- Debt/Equity 1.6018
- CurrentRatio 1.5791
- ROIC 0.302
- MktCap 998599985920.0
- FreeCF/Share 9.9911
- PFCF 111.3018
- PE 46.0595
- Debt/Assets 0.3779
- DivYield 0.0059
- ROE 0.9785
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LLY | Barclays | -- | Overweight | -- | $1350 | Feb. 20, 2026 |
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
News
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Neutral
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
Read More
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Published: February 23, 2026 by: CNBC
Sentiment: Positive
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug.
Read More
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect* INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice …
Read More
Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value
Published: February 23, 2026 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it fell as much as 15% in Europe), after it disclosed that CagriSema did not meet its primary objective of demonstrating non-inferiority to Lilly's tirzepatide in terms of weight loss over 84 weeks.
Read More
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Published: February 23, 2026 by: Market Watch
Sentiment: Negative
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Published: February 23, 2026 by: CNBC
Sentiment: Negative
The drug, CagriSema, didn't achieve its primary endpoint of demonstrating non-inferiority on weight loss. In this article NVO
Read More
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
Published: February 23, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing body weight.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
Published: February 19, 2026 by: PRNewsWire
Sentiment: Neutral
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's disease INDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh …
Read More
1 Reason I'd Buy Eli Lilly Stock and Never Sell
Published: February 17, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly has been busy building its drug pipeline for the future. The company currently sells the world's best-selling drug.
Read More
Why Eli Lilly's $1 Billion AI Bet Could Reshape Drug Discovery
Published: February 16, 2026 by: 24/7 Wall Street
Sentiment: Positive
As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high.
Read More
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exceptional Corporate Resilience profile and attractive sustainability opportunity set in areas like the Digital Infrastructure build-out. Oracle stands out with a strong sustainability profile, offering notable opportunities in Digital Infrastructure, Education and the development of Enhanced Skills & Innovation.
Read More
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
Published: February 16, 2026 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 3:10 p.m.
Read More
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
Published: February 12, 2026 by: Reuters
Sentiment: Positive
Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration in April.
Read More
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market
Published: February 12, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S (NYSE: NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE: LLY) as competition intensifies in the fast-growing weight-loss market.
Read More
2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
Published: February 12, 2026 by: 24/7 Wall Street
Sentiment: Positive
AI-assisted drug discovery isn't just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age.
Read More
How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY's Q4 beat and bold 2026 outlook highlight surging GLP-1 sales and a deep obesity pipeline.
Read More
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.
Read More
Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with EPS up over 40% in 2026.
Read More
Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments
Published: February 09, 2026 by: Benzinga
Sentiment: Positive
The strategic move is seen as a significant step in enhancing Lilly's capabilities in genetic medicine, adding pressure as broader markets edged lower.
Read More
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments
Published: February 09, 2026 by: Benzinga
Sentiment: Positive
The strategic move is seen as a significant step in enhancing Lilly's capabilities in genetic medicine, adding pressure as broader markets edged lower.
Read More
Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic
Published: February 05, 2026 by: Schwab Network
Sentiment: Positive
After Eli Lilly (LLY) posted earnings that outshined Novo Nordisk's (NVO) decelerating growth, Scott Zari feels comfortable calling Eli Lilly the dominant winner in the weight loss drug race. While he notes Novo Nordisk's pill as "important" to consumers, it's Eli Lilly's injectable he sees continuing to lead GLP-1 momentum.
Read More
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Published: February 05, 2026 by: CNBC
Sentiment: Negative
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.
Read More
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
Published: February 05, 2026 by: MarketBeat
Sentiment: Neutral
The first week of February 2026 will be remembered as the day the pharmaceutical sector's most famous partnership officially dissolved. For years, Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO traded in lockstep, their stock charts nearly identical as they raced to supply the world with weight-loss medicines.
Read More
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Published: February 04, 2026 by: CNBC
Sentiment: Positive
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ahead thanks to its blockbuster medicines.
Read More
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturing investments and pipeline strength, especially tirzepatide and retatrutide, position it to outpace Novo Nordisk A/S in the GLP-1/obesity market. NVO faces 2026 revenue and profit declines due to U.S. pricing pressures, patent expiries, and manufacturing disadvantages despite a strong dividend yield.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000